admin – Page 4264 – Get News Story

Autosomal Dominant Polycystic Kidney Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX

The Key Autosomal Dominant Polycystic Kidney Disease Companies in the market include – Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others.

DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Autosomal Dominant Polycystic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autosomal Dominant Polycystic Kidney Disease Market Forecast

Some of the key facts of the Autosomal Dominant Polycystic Kidney Disease Market Report:

The Autosomal Dominant Polycystic Kidney Disease market size was valued approximately ~USD 1,476 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In October 2024, Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company dedicated to discovering and developing innovative medicines targeting microRNAs, announced today that it has completed enrollment of 26 patients in the fourth cohort of the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
In April 2024, Eloxx Pharmaceuticals made significant progress in developing ELX-02 for treating Alport syndrome with Nonsense Mutations (NMAS). Furthermore, through its global licensing agreement with Almirall announced in March, the company has initiated the development of ZKN-013 for treating Recessive Dystrophic Epidermolysis Bullosa (RDDEB) and Familial Adenomatous Polyposis (FAP) patients with nonsense mutations. A recent publication on Autosomal Dominant Polycystic Kidney Disease (ADPKD) highlights the potential of ELX-02 in treating all rare genetic kidney diseases with nonsense mutations in the disease-causing genes.
In 2023, the US market was valued at around USD 889.8 million. This figure is expected to shift with the introduction of emerging therapies throughout the forecast period (2024-2034).
In 2023, the combined market size of EU4 and the UK was approximately USD 7,395 million, representing nearly 39.4% of the total 7MM market.
In the EU4 and the UK, the UK had the largest autosomal dominant polycystic kidney disease market size at around USD 72.5 million, followed by France with approximately USD 65.6 million and Spain with USD 29.4 million. These figures are projected to shift by 2034.
In 2023, Japan represented about 26% of the total Autosomal Dominant Polycystic Kidney Disease market across the 7MM. These proportions are expected to shift by 2034.
According to DelveInsight’s analysis, the total diagnosed prevalent cases of autosomal dominant polycystic kidney disease in the 7MM were approximately 194,251 in 2023. This number is expected to change during the forecast period from 2024 to 2034.
In 2023, the US reported approximately 144,697 diagnosed prevalent cases of autosomal dominant polycystic kidney disease.
In 2023, the UK reported the highest number of autosomal dominant polycystic kidney disease diagnosed prevalent cases among the EU4 and the UK, with approximately 68,138 cases, followed by France with 61,676 cases. Italy had the lowest, with nearly 16,476 cases.
Key Autosomal Dominant Polycystic Kidney Disease Companies: Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others
Key Autosomal Dominant Polycystic Kidney Disease Therapies: JYNARQUE/ JINARC/SAMSCA (tolvaptan), VX-407, Bosutinib, Tolvaptan, Lixivaptan, Everolimus, OPC-41061, Rapamune, XRx-008, Bardoxolonemethyl, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and others
The ADPKD epidemiology based on mutation-specific cases analyzed that the mutation-specific distribution of the disease suggests a higher prevalence of ADPKD due to mutation in PKD1 gene than in PKD2 gene
The Autosomal Dominant Polycystic Kidney Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Autosomal Dominant Polycystic Kidney Disease pipeline products will significantly revolutionize the Autosomal Dominant Polycystic Kidney Disease market dynamics.

Autosomal Dominant Polycystic Kidney Disease Overview

Autosomal Dominant Polycystic Kidney Disease is a genetic disorder characterized by the development of numerous fluid-filled cysts primarily within the kidneys. It is one of the most common inherited kidney disorders.

Get a Free sample for the Autosomal Dominant Polycystic Kidney Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market

Autosomal Dominant Polycystic Kidney Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation:

The Autosomal Dominant Polycystic Kidney Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Autosomal Dominant Polycystic Kidney Disease
Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease by severity
Gender-specific Prevalence of Autosomal Dominant Polycystic Kidney Disease
Diagnosed Cases of Episodic and Chronic Autosomal Dominant Polycystic Kidney Disease

Download the report to understand which factors are driving Autosomal Dominant Polycystic Kidney Disease epidemiology trends @ Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast

Autosomal Dominant Polycystic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autosomal Dominant Polycystic Kidney Disease market or expected to get launched during the study period. The analysis covers Autosomal Dominant Polycystic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Autosomal Dominant Polycystic Kidney Disease Therapies and Key Companies

JYNARQUE/ JINARC/SAMSCA (tolvaptan): Otsuka America Pharmaceuticals
VX-407: Vertex Pharmaceuticals
Bosutinib: Pfizer
Tolvaptan: Otsuka Pharma
Lixivaptan: Palladio Biosciences
Everolimus: Novartis Pharma
OPC-41061: Otsuka Pharma
Rapamune: Pfizer
XRx-008: XORTX Therapeutic
Bardoxolonemethyl: ReataPharmaceuticals/ Kyowa Kirin
Tesevatinib/KD019: Sanofi
GLPG2737: Galapagos NV
JNJ-0237/AT-20494: Janssen Pharmaceuticals
RGLS8429: RegulusTherapeutics

Discover more about therapies set to grab major Autosomal Dominant Polycystic Kidney Disease market share @ Autosomal Dominant Polycystic Kidney Disease Treatment Landscape

Autosomal Dominant Polycystic Kidney Disease Market Drivers

Technological advances in diagnostic procedures due to an increasing focus on early diagnosis has reduced undiagnosed cases, thus persistent rising cases of diagnosed ADPKD offer opportunities to companies to launch new therapies in the market.
Advances are being made in unravelling the genetic origins of ADPKD, in non-invasive monitoring and in predicting disease progression that will help in better disease management

Autosomal Dominant Polycystic Kidney Disease Market Opportunities

Pre-symptomatic diagnosis and their application in the care and management of individuals at risk for ADPKD.
Identification of biomarkers for early detection of ADPKD patients at high risk for progression will help better manage ADPKD patients and prevent their progression.

Scope of the Autosomal Dominant Polycystic Kidney Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Autosomal Dominant Polycystic Kidney Disease Companies: Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others
Key Autosomal Dominant Polycystic Kidney Disease Therapies: JYNARQUE/ JINARC/SAMSCA (tolvaptan), VX-407, Bosutinib, Tolvaptan, Lixivaptan, Everolimus, OPC-41061, Rapamune, XRx-008, Bardoxolonemethyl, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and others
Autosomal Dominant Polycystic Kidney Disease Therapeutic Assessment: Autosomal Dominant Polycystic Kidney Disease current marketed and Autosomal Dominant Polycystic Kidney Disease emerging therapies
Autosomal Dominant Polycystic Kidney Disease Market Dynamics: Autosomal Dominant Polycystic Kidney Disease market drivers and Autosomal Dominant Polycystic Kidney Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Autosomal Dominant Polycystic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement

To know more about Autosomal Dominant Polycystic Kidney Disease companies working in the treatment market, visit @ Autosomal Dominant Polycystic Kidney Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Autosomal Dominant Polycystic Kidney Disease Market Report Introduction

2. Executive Summary for Autosomal Dominant Polycystic Kidney Disease

3. SWOT analysis of Autosomal Dominant Polycystic Kidney Disease

4. Autosomal Dominant Polycystic Kidney Disease Patient Share (%) Overview at a Glance

5. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance

6. Autosomal Dominant Polycystic Kidney Disease Disease Background and Overview

7. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Autosomal Dominant Polycystic Kidney Disease

9. Autosomal Dominant Polycystic Kidney Disease Current Treatment and Medical Practices

10. Autosomal Dominant Polycystic Kidney Disease Unmet Needs

11. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies

12. Autosomal Dominant Polycystic Kidney Disease Market Outlook

13. Country-Wise Autosomal Dominant Polycystic Kidney Disease Market Analysis (2020–2034)

14. Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement of Therapies

15. Autosomal Dominant Polycystic Kidney Disease Market Drivers

16. Autosomal Dominant Polycystic Kidney Disease Market Barriers

17. Autosomal Dominant Polycystic Kidney Disease Appendix

18. Autosomal Dominant Polycystic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Autosomal Dominant Polycystic Kidney Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX

Hayes A-Z Electronics LLC Launches New “HAZE” Brand Focused on Office Comfort Products

Hayes A-Z Electronics LLC is thrilled to announce the launch of HAZE, its new brand specializing in premium office chair wheels and ergonomic seat cushions. Designed to enhance comfort, mobility, and productivity, HAZE products combine durability, performance, and ergonomic design to transform workspaces.

Atlanta, Georgia – Hayes A-Z Electronics LLC, a leader in innovative products and solutions, is proud to announce the launch of its new product brand, HAZE. The HAZE brand will specialize in offering premium office chair wheels and seat cushions designed to enhance comfort, productivity, and mobility for office workers worldwide.

With a commitment to quality and customer satisfaction, HAZE is dedicated to creating products that provide long-lasting durability, superior performance, and an ergonomic advantage. The HAZE office chair wheels are engineered for smooth rolling, reducing friction and wear on both carpets and hard floors. Paired with the brand’s premium seat cushions, these products are designed to improve posture and reduce pressure points during long hours of seated work.

“We are excited to introduce HAZE as a brand that will bring innovative solutions to enhance the office experience,” said Joshua Hayes, CEO of Hayes A-Z Electronics LLC. “We understand the importance of comfort and efficiency in the workplace, and HAZE will help our customers create a workspace that supports both their productivity and well-being.”

The HAZE product line has been introduced to enhance comfort and functionality in workspaces. Each HAZE product reflects a strong commitment to quality and durability. Designed for both home offices and corporate environments, the products will be available on the company’s website, major e-commerce platforms, and the official HAZE Amazon Store on March 1st, 2025.

About Hayes A-Z Electronics LLC

Hayes A-Z Electronics LLC is an innovative technology company focused on creating high-quality consumer products that improve everyday life. With a track record of excellence in design and production, the company strives to provide solutions that offer both functionality and value. Through its new HAZE brand, Hayes A-Z Electronics LLC is expanding its reach to the office products market, offering tools to enhance workplace comfort.

Media Contact
Company Name: Hayes A-Z Electronics LLC
Contact Person: Joshua Hayes
Email: Send Email
Phone: 678-446-7952
Country: United States
Website: https://ha-ze.com

Kerri Gene Daniels’ Glorified UN-Expectations is a Remarkable True Story of Faith, Hope, and Healing through Grief

In Glorified UN-Expectations – Trusting God for His Unfailing Faith, Hope, and Love, award-winning author Kerri Gene Daniels shares her inspiring journey from despair to hope, as she turns to God in moments of deep grief and loss. A remarkable story of a truly extraordinary life, Kerri serves as a glowing example of what it means to find strength, hope, and healing amidst life’s most challenging moments.

Kerri Gene Daniels is an award-winning author and passionate storyteller based in Adrian, Michigan. Kerri holds many cherished roles in her life: she is a devoted wife, mother, grandmother, friend, and daughter. Having the unique bond of being an identical twin to her best friend, Sherri adds a special layer to her life’s journey.

Kerri’s life embodies a heartwarming mix of love and devotion. When she isn’t supporting her husband on the farm, Kerri loves to sit on her back porch, overlooking their farmland, and play guitar. Above all else, Kerri loves singing the praises of her Lord and her Savior, Christ Jesus and uplifting others through her ministry work.

Kerri’s debut memoir, Glorified UN-Expectations – Trusting God for His Unfailing Faith, Hope, and Love, is a powerful testament to the transformative power of having unwavering faith in Jesus Christ. Drawing from her life’s most painful tragedies, Kerri reveals how moments of deep loss can become opportunities to seek God, embrace healing, and find purpose amid adversity. Her inspiring story invites readers to rise above unexpected challenges, embrace hope, and find joy even in life’s most painful moments. This one-on-one interview shares Kerri’s background and experience writing the book.

Tell us about Glorified UN-Expectations – Trusting God for His Unfailing Faith, Hope, and Love.

Glorified UN-Expectations reveal the extraordinary ways God’s presence can be discovered amid life’s most unpredictable challenges. It recounts how my family and I overcame seemingly insurmountable hardships, but were held together by the unbreakable bonds of faith, hope, and love. The profound lessons I share were inspired by my three children: Jacob, Elijah, and Jaelynn—each of whom shaped my journey in remarkable ways.

Through Jacob’s story, I discovered the transformative power of faith as I had to trust that God would answer my prayers and bring a loving man into my life who would embrace both me and Jacob unconditionally.

Elijah taught me about the significance of hope. Despite facing ongoing health challenges from Cerebral Palsy, Epilepsy, Autism and many other health issues, his strength reminds me to hold fast to the belief that God’s healing and grace are ever-present, guiding us through even the most trying times.

Jaelynn’s story was a profound lesson in love. The heart-wrenching experience of losing a child became a powerful opportunity to share the love of Jesus and the message of salvation with hundreds during her celebration of life service—and now, with readers of this book.

Glorified UN-Expectations is meant to offer hope and inspiration to anyone navigating life’s challenges, reminding us that even in the darkest moments, there is a path to healing, purpose, and grace.

What inspired you to write Glorified UN-Expectations – Trusting God for His Unfailing Faith, Hope, and Love?

God, my husband, and our three beloved children, Jacob, Elijah, and Jaelynn, inspired me to write this book.

It all started with a dream, quite literally. One night, God revealed to my husband that I was meant to share my story through writing. At first, I hesitated, afraid to revisit the painful chapters of my life when everything felt like it was falling apart. Yet, I came to realize that avoiding this calling would mean missing out on the beautiful miracles God had shown me during my struggles.

Encouraged by the loving support of those who believed my journey could resonate with others, I found the courage to embrace the challenge. There were moments when I felt completely overwhelmed and thought that writing a book was beyond my reach, but during those times, God opened doors I never expected. It became possible for me to share my journey, not just for myself, but to reflect His glory and the hope that can arise from even the darkest times.

What is one message you would like readers to remember?

This book shares a powerful message about how God can turn even the most tragic situations into valuable opportunities to uplift and support others.

It serves as a reminder that while we may not always receive the answers we long for, pouring our hearts into seeking God can reveal His goodness and purpose in our lives.

Through this journey, we can truly experience His grace and mercy, bringing hope, healing, and purpose, even in our most challenging times.

Purchasing the Book

Glorified UN-Expectations – Trusting God for His Unfailing Faith, Hope, and Love has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Book Excellence writes, “A deeply moving exploration of faith that feels both personal and universal. Glorified Un-Expectations remind us of the beauty in trusting God’s plan and that love, hope, and grace are always within reach, even when the path seems uncertain.” In addition, a reviewer from Reader’s Favorite Divine Zape writes, “As I read this book, I had the time to look back at my own story and to understand how God has been present, even in very difficult moments. It’s a real gift of faith.“

Readers are encouraged to access a FREE digital copy of the book today: https://issuu.com/craigruhl/docs/glorified_un-expectations_complete_final_4-19-20

To connect with Kerri, watch the book trailer, and learn more about her work, visit: https://kerridanielsministries.com/.

You can email her at info@kerridanielsministries.com or kgd320@gmail.com.

You can also find her on Linkedin and Facebook and TikTok along with her son Elijah, sharing his 3000+ Monster Truck Collection. https://www.tiktok.com/@kerrigd?_t=ZT-8tIVEQtLJow&_r=1

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Kerri Gene Daniels’ Glorified UN-Expectations is a Remarkable True Story of Faith, Hope, and Healing through Grief

Breast Cancer FDA Approvals, Pipeline Insights, Clinical Trials, Emerging Drugs and Companies | DelveInsight

DelveInsight’s, “Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Breast Cancer Treatment Landscape. Click here to read more @ Breast Cancer Pipeline Outlook

Key Takeaways from the Breast Cancer Pipeline Report

In January 2025:- Olive Healthcare:- A Multi-center, Open-label, Single Arm, Prospective Pivotal Medical Device Clinical Trial to Evaluate Efficacy and Safety of Study Device (ORIGO) That Provides Numerical Data by Measuring the Composition Within Breast Tissue Using Diffusion Optical Spectroscopy Imaging Technology to Assist in the Differential Diagnosis of Breast Tumors in Patients with Breast Lesions.
In January 2025:- Eli Lilly and Company:- The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
In January 2025:- Novartis Pharmaceuticals:- This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study conducted in Chinese men and postmenopausal women with HR- positive, HER2-negative, PIK3CA mutant advanced breast cancer which progressed on or after AI treatment. The study also includes a single arm, open-label cohort (the PK cohort) to conduct pharmacokinetic analysis.
DelveInsight’s Breast Cancer pipeline report depicts a robust space with 100+ Breast Cancer companies working to develop 120+ pipeline therapies for Breast Cancer treatment.
The leading Breast Cancer Companies such as Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
Promising Breast Cancer Therapies such as Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

Discover groundbreaking developments in Breast Cancer therapies! Gain in-depth knowledge of key Breast Cancer clinical trials, emerging drugs, and market opportunities @ Breast Cancer Clinical Trials Assessment

Breast Cancer Emerging Drugs Profile

SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.

SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells.

HLX11: Shanghai Henlius Biotech

HLX11 is a pertuzumab biosimilar developed by Henlius independently in line with relevant regulations and guidelines on biosimilars in China and the European Union (EU), which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2-positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic or unresectable locally recurrent breast cancer patients. HLX11 can specifically bind with the subdomain II of HER2 extracellular domain and inhibit the heterodimerisation of HER2 and other HER family receptors, i.e., EGFR, HER3, and HER4. This will inhibit signal transduction of relevant pathways and lead to the stop of growth and apoptosis of tumour cells. In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive Breast Cancer.

Praluzatamab ravtansine: CytomX Therapeutics

Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enriched for proteases capable of cleaving the linker, thereby releasing the mask, allowing for localized binding of CX-2009 to CD166. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer.

MCLA-128: Merus N.V.

MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics® that utilizes Merus Dock & Block® mechanism and inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors. MCLA-128 is believed to target the HER3 signaling pathway and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment and enhancement of immune effector cells to eliminate the tumor. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, which is developed based on Biclonics ENGAGE platform. Currently the drug is in the Phase II stage of clinical trial evaluation for the treatment of Breast Cancer.

DX126 262: Hangzhou DAC Biotech

DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable locally advanced or metastatic non-squamous NSCLC, Breast Cancer, breast cancer. The drug candidate is an antibody drug conjugate comprising recombinant humanized anti-Her2 monoclonal antibody conjugated to Tub-114. It is formulated as lyophilized powder and administered via intravenous route of administration. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.

Stay informed about the Breast Cancer pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Breast Cancer Unmet Needs

Breast Cancer Companies

Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Breast Cancer Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Transform your understanding of the Breast Cancer Pipeline! See the latest progress in drug development and clinical research @ Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Breast Cancer Pipeline Report

Coverage- Global
Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
Breast Cancer Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Breast Cancer Pipeline Analysis Today! @ Breast Cancer Drugs and Companies

Table of Content

Introduction
Executive Summary
Breast Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Breast Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
MCLA-128: Merus N.V.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DX126 262: Hangzhou DAC Biotech
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
ES2B C001: ExpreS2ion Biotechnologies
Drug profiles in the detailed report…..
Inactive Products
Breast Cancer Key Companies
Breast Cancer Key Products
Breast Cancer- Unmet Needs
Breast Cancer- Market Drivers and Barriers
Breast Cancer- Future Perspectives and Conclusion
Breast Cancer Analyst Views
Breast Cancer Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Cancer FDA Approvals, Pipeline Insights, Clinical Trials, Emerging Drugs and Companies | DelveInsight

Boston Restoration Prime Celebrates Over 25 Years of Excellence in Property Restoration

Honoring a Legacy of Quality Service and Customer Commitment in Boston

Boston, MA – Boston Restoration Prime, a trusted leader in property restoration services, proudly marks over 25 years of dedicated service to the Boston community. Since its inception in 1997, the company has set the standard for excellence in water, fire, and mold damage restoration, helping thousands of homeowners and businesses recover from property disasters with efficiency and care.

“This milestone reflects our unwavering commitment to providing top-notch restoration solutions,” said James Williams, spokesperson for Boston Restoration Prime. “We are honored to serve the Boston area, and we remain focused on delivering exceptional service that our clients can rely on during their most challenging times.”

Founded with the mission to restore properties while offering peace of mind, Boston Restoration Prime has grown into a cornerstone of the community. The company’s success is rooted in its highly skilled team, state-of-the-art equipment, and environmentally friendly practices. Over the years, they have expanded their services to include storm cleanup, trauma scene remediation, and odor removal, staying ahead of industry trends to meet evolving customer needs.

Boston Restoration Prime has also prioritized building strong relationships with local insurance providers, ensuring a smooth claims process for clients. This commitment to comprehensive service has earned them numerous accolades and a loyal customer base.

As the company celebrates this significant milestone, it is also looking to the future. Boston Restoration Prime plans to further enhance its services by adopting cutting-edge restoration technologies and expanding its community outreach programs.

“We are constantly seeking ways to improve and give back to the community that has supported us for over two decades,” added Williams. “Our focus is not just on restoring properties but also on building lasting relationships with our clients and partners.”

Boston Restoration Prime specializes in comprehensive property restoration services, including water, fire, and mold damage remediation. Established in 1997, the company is known for its rapid emergency response, skilled technicians, and environmentally conscious practices. With a customer-first approach, Boston Restoration Prime has become a trusted name in the Boston area for restoring homes and businesses to their original condition.

Media Contact
Company Name: Boston Restoration Prime
Contact Person: James Williams
Email: Send Email
Phone: 617-639-0909
Country: United States
Website: https://bostonmarestoration.com

Sawyer Twain Redefines Luxury Game Room Furniture with Steel Pool Tables and Other Modern Designs

One name stands out from the crowd when it comes to luxury game room furniture like steel and slate pool tables. Discover why Sawyer Twain earned a reputation as America’s leading high-quality, niche gaming furniture provider.

Sawyer Twain goes beyond retail as the United States’ ultimate destination for luxury game room furniture. The company combines unparalleled craftsmanship and sophisticated designs for a modern twist on pool tables with its exclusive collection of steel pool tables. Elevate the space with a timelessly elegant slate steel pool table representing the perfect fusion of strength, durability, and style.

“Every table in this collection is built with precision-engineered steel frames and professional-grade slate surfaces,” the company’s founders said. “Whether you’re designing a personal game room or upgrading a commercial interior, Sawyer Twain’s steel pool tables promise to make a bold statement while delivering world-class playability.”

Sawyer Twain carries the world’s top pool table brands in its steel collection. From the sleek, minimalist designs of the Felix table from Plank & Hide to the fully customizable, handcrafted masterpieces from Doc & Holliday, customers can find the best in luxury steel pool tables at Sawyer Twain.

Consumers frequently turn to Sawyer Twain for luxury that lasts a lifetime. The exclusive steel pool table collection offers more than durability; it creates stunning centerpieces that transform spaces and spark connections.

“At Sawyer Twain, we don’t just sell pool tables — we redefine what they can be,” company representatives said. “Every table is crafted with the finest materials, from precision-engineered steel to professional-grade slate, ensuring your investment stands the test of time.”

The dedicated team at Sawyer Twin delivers much more than furniture. Enjoy an effortless, stress-free installation with the company’s white-glove service. From order to assembly, customers can expect a seamless process where they are the focus. Sawyer Twain’s elite collection offers options that combine timeless designs with unmatched durability and precise play, no matter what a client wants in a steel pool table.

“From the sleek sophistication of the Felix to the fully customizable Tron and Jett and the bold industrial edge of the Jaxx, there’s a steel pool table to fit your vision. Whether you’re upgrading your home or designing a high-end commercial space, Sawyer Twain has the perfect centerpiece to elevate your game,” the company’s founders said.

Visit the Sawyer Twain website or call 800-503-0531 to learn more about the expansive selection of slate steel pool tables and other luxury game room furniture. Sign up for the Sawyer Twin newsletter for a first-purchase discount and updates with special offers. Follow the company on Instagram and Facebook for social media updates.

Media Contact
Company Name: Sawyer Twain
Contact Person: Sales
Email: Send Email
Phone: 800-503-0531
Country: United States
Website: https://www.sawyertwain.com/

LiTime Launches Its First Plug-and-Play Lithium Golf Cart Batteries and Seeks Golf Enthusiasts for the LiTime Pro Program

LiTime, a leader in lithium iron phosphate (LiFePO4) battery technology, officially launched its first plug-and-play LiTime 48V (51.2V) 100Ah golf cart lithium battery on January 8 this year. Featuring an integrated mounting bracket, positioning plate, and a convenient top handle, the battery significantly simplifies the installation process, providing users with a hassle-free experience. Additionally, LiTime is inviting golfers and enthusiasts worldwide to join its “LiTime Pro Club” program.

275c68f739242942607858d8d0d869cf

LiTime Pro Club Recruitment Program for Golfers and Enthusiasts

To further explore the potential of lithium iron phosphate batteries in different applications and to thank its loyal customers, LiTime has launched the “LiTime Pro Club”. The program seeks enthusiasts who share LiTime’s brand values, are familiar with the company’s product features, and can effectively engage with consumers in a variety of fields.

LiTime will offer sponsorship and platform support to these Pro players, helping them achieve personal milestones and push boundaries in their careers. By partnering with LiTime, Pro players not only get the chance to showcase their talents but also open doors to even greater achievements.

If you’re passionate about golf and want to grow alongside LiTime, they invite you to join the LiTime Pro Club and contribute to the continued growth of the brand. Please reach out to LiTime via email at: collabconnect@litime.com.

LiTime 48V Lithium Golf Cart Batteries

The LiTime 48V 100Ah lithium golf cart battery features a custom-designed mounting bracket at the bottom. When replacing the old battery, users can easily position the new battery using the included positioning plate, ensuring it is securely fixed. The top handle design further simplifies handling and installation, making the replacement process straightforward and greatly improving the overall user experience. This battery also comes with the following features:

8f1ab98fa977428dbd2d8c792acc649c

Real-Time Battery Status Display: Unlike traditional golf cart batteries, which offer no way to monitor battery status, LiTime’s battery addresses this concern by offering a display that is fully compatible with the same communication protocol. Users can view critical information such as the battery’s state of charge (SOC), voltage, current, temperature, and more in real time, giving golfers peace of mind by removing any uncertainty about battery status and enhancing their overall experience.
Proprietary BMS Provides Comprehensive Safety: The LiTime 48V golf cart battery is equipped with a powerful 200A battery management system (BMS), designed specifically for high-load and high-performance applications. The system can manage current outputs of 600A (1 second), 360A (10 seconds), and 200A (120 seconds), ensuring the battery runs smoothly and safely even during intense activities like acceleration or climbing hills. The BMS also includes 20 safety protocols that prevent issues such as overcharging, overdischarging, overcurrent, overheating, low temperatures, and short circuits, ensuring long-term stability and safety in complex conditions. The battery also features an internal vent valve that helps stabilize internal pressure, providing extra safety under extreme use. The battery’s intelligent management system, operating through RS485/CAN communication protocols, enables precise monitoring and performance management, ensuring the battery’s status is always under control, offering users a safer and more reliable experience.
EV LiFePO4 Cells Provide Extended Range: All LiTime products are equipped with highly efficient EV LiFePO4 cells, which offer over 4000 charge cycles at 100% depth of discharge (DOD), ensuring a lifespan of over 10 years. With top-quality cells, the LiTime 48V golf cart battery delivers 5120Wh of energy per unit. In real-world tests, a fully charged battery can power a golf cart for about 46 miles—roughly the equivalent of 10 full rounds on a standard 18-hole golf course. This makes the battery more than capable of meeting long-use demands on the course, providing electric golf carts with steady, reliable power. For more in-depth information, please check out the article “How Long Do Golf Cart Batteries Last,” written by LiTime’s technical support team.

The LiTime 48V 100Ah lithium golf cart battery is priced at $1999.99, with a limited-time special bundle price of $1299.99 for the set (which includes the battery, 58.4V 18A charger, and display screen) during the product launch period. For additional user reviews of LiTime batteries, please visit LiTime Battery Review.

About LiTime

LiTime is a company with 16 years of experience in the new energy storage sector. Focused on user needs and powered by technological innovation, LiTime continually pushes forward in its mission to deliver the best value in lithium iron phosphate batteries. To date, LiTime’s battery technology has earned more than 380 product certifications. Guided by the brand philosophy of “Life & Discovery,” LiTime stands as an industry leader, dedicated to providing green, sustainable, and efficient energy solutions, while making a significant contribution to reducing the global carbon footprint and reshaping the power grid landscape.

Media Contact
Company Name: Shenzhen LiTime Technology Co., Ltd
Contact Person: Shafee Chang
Email: Send Email
Country: China
Website: www.litime.com

Treatment Resistant Depression Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutic

The Key Treatment Resistant Depression Companies in the market include – Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others.

DelveInsight’s “Treatment Resistant Depression Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Treatment Resistant Depression, historical and forecasted epidemiology as well as the Treatment Resistant Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Treatment Resistant Depression, offering comprehensive insights into the Treatment Resistant Depression revenue trends, prevalence, and treatment landscape. The report delves into key Treatment Resistant Depression statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Treatment Resistant Depression therapies. Additionally, we cover the landscape of Treatment Resistant Depression clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Treatment Resistant Depression treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Treatment Resistant Depression space.

To Know in detail about the Treatment Resistant Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Treatment Resistant Depression Market Forecast

Some of the key facts of the Treatment Resistant Depression Market Report:

The Treatment Resistant Depression market size was valued ~USD 3,100 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In October 2024, Denovo Biopharma LLC, a leader in utilizing precision medicine for the development of innovative drugs, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DB104 (liafensine) for the treatment of patients with treatment-resistant depression (TRD). Fast Track designation can accelerate the review process for drugs intended to treat serious or life-threatening conditions and that show potential to meet an unmet medical need for such conditions.
In March 2024, atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, announced today encouraging initial results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in Treatment Resistant Depression (TRD), a condition impacting roughly 100 million people globally
In 2022, the United States held the largest share of the Treatment-Resistant Depression market among the 7MM, with a market size of approximately USD 2,400 million. This figure is projected to grow further by 2032.
In 2022, the UK had a market size of approximately USD 110 million, and it is projected to grow further during the forecast period.
In January 2025, The FDA approved Johnson & Johnson’s Spravato (esketamine) as the first and only standalone treatment specifically for treatment-resistant depression (TRD).
In November 2024, In Q3 2024, atai Life Sciences shared updates on its pipeline, highlighting the FDA’s approval of an Investigational New Drug (IND) application for VLS-01, a buccal film formulation of DMT. The company aims to commence a Phase 2 trial of VLS-01 for treatment-resistant depression by the end of the year. Furthermore, atai is on schedule to initiate a Phase 2 study of EMP-01 (oral R-MDMA) for social anxiety disorder by late 2024.
In October 2024, Denovo Biopharma LLC announced that the FDA has awarded Fast Track designation to DB104 (liafensine), a treatment under development for treatment-resistant depression (TRD). This designation could accelerate the review process for DB104, a therapy aimed at addressing the significant unmet need for patients unresponsive to standard antidepressant treatments.
Key Treatment Resistant Depression Companies: Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others

Key Treatment Resistant Depression Therapies: SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), GH001, VLS-01-203 BU, BPL-003, Psilocybin, NV-5138, Liafensine, Psilocybin, PCN-101, and others
The Treatment Resistant Depression market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Treatment Resistant Depression pipeline products will significantly revolutionize the Treatment Resistant Depression market dynamics
Emerging therapies for Treatment-Resistant Depression, such as Novartis’ MIJ821, COMPASS Pathways’ COMP360 (Psilocybin), Beckley Psytech’s BPL-003, Navitor Pharmaceuticals’ NV-5138, and others, hold the potential to significantly impact and drive growth in the Treatment-Resistant Depression market.
In 2022, the total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM were around 6,409,000 and are expected to rise throughout the forecast period (2023–2032.
In 2022, the United States accounted for the majority of diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM, comprising approximately 71% of the total cases. In comparison, the EU4 and the UK represented around 25%, while Japan contributed approximately 4% of the diagnosed cases in the 7MM.
According to DelveInsight, approximately 512,000 cases of Treatment-Resistant Depression were reported in males and 1,117,000 cases in females across the EU4 and the UK in 2022. These numbers are expected to rise over the forecast period.
In 2022, the highest number of Treatment-Resistant Depression cases in the US was observed in individuals aged 50–60 years, while the lowest number was recorded in the 18–29-year age group.

Treatment Resistant Depression Overview

Treatment-Resistant Depression (TRD) refers to a form of major depressive disorder (MDD) that does not respond adequately to standard antidepressant treatments. Patients are typically diagnosed with TRD if their symptoms persist despite undergoing at least two different antidepressant therapies, each at an adequate dose and duration.

Get a Free sample for the Treatment Resistant Depression Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market

Treatment Resistant Depression Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Treatment Resistant Depression Epidemiology Segmentation:

The Treatment Resistant Depression market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Treatment Resistant Depression
Prevalent Cases of Treatment Resistant Depression by severity
Gender-specific Prevalence of Treatment Resistant Depression
Diagnosed Cases of Episodic and Chronic Treatment Resistant Depression

Download the report to understand which factors are driving Treatment Resistant Depression epidemiology trends @ Treatment Resistant Depression Epidemiology Forecast

Treatment Resistant Depression Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Treatment Resistant Depression market or expected to get launched during the study period. The analysis covers Treatment Resistant Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Treatment Resistant Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Treatment Resistant Depression Therapies and Key Companies

SPRAVATO (esketamine): Johnson & Johnson
MIJ821: Novartis
COMP360 (Psilocybin): COMPASS Pathways
GH001: GH Research Ireland Limited
VLS-01-203 BU: atai Therapeutics, Inc.
BPL-003: Beckley Psytech Limited
Psilocybin: COMPASS Pathways
NV-5138: Navitor Pharmaceuticals
Liafensine: Denovo Biopharma
Psilocybin: COMPASS Pathway
PCN-101: Perception Neuroscience

Discover more about therapies set to grab major Treatment Resistant Depression market share @ Treatment Resistant Depression Treatment Landscape

Treatment Resistant Depression Market Drivers

Emerging Treatment Resistant Depression Therapies
Increased Awareness and Diagnosis
Advances in Personalized Medicine
Rising Prevalence of Depression
Improved Access to Mental Health Care
Government and Institutional Support

Treatment Resistant Depression Market Barriers

High Cost of Treatments
Limited Availability of Effective Therapies
Stigma Surrounding Mental Health
Side Effects and Safety Concerns
Regulatory Challenges
Lack of Long-term Data

Scope of the Treatment Resistant Depression Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Treatment Resistant Depression Companies: Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others
Key Treatment Resistant Depression Therapies: SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), GH001, VLS-01-203 BU, BPL-003, Psilocybin, NV-5138, Liafensine, Psilocybin, PCN-101, and others
Treatment Resistant Depression Therapeutic Assessment: Treatment Resistant Depression current marketed and Treatment Resistant Depression emerging therapies
Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression market drivers and Treatment Resistant Depression market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Treatment Resistant Depression Unmet Needs, KOL’s views, Analyst’s views, Treatment Resistant Depression Market Access and Reimbursement

To know more about Treatment Resistant Depression companies working in the treatment market, visit @ Treatment Resistant Depression Clinical Trials and Therapeutic Assessment

Table of Contents

1. Treatment Resistant Depression Market Report Introduction

2. Executive Summary for Treatment Resistant Depression

3. SWOT analysis of Treatment Resistant Depression

4. Treatment Resistant Depression Patient Share (%) Overview at a Glance

5. Treatment Resistant Depression Market Overview at a Glance

6. Treatment Resistant Depression Disease Background and Overview

7. Treatment Resistant Depression Epidemiology and Patient Population

8. Country-Specific Patient Population of Treatment Resistant Depression

9. Treatment Resistant Depression Current Treatment and Medical Practices

10. Treatment Resistant Depression Unmet Needs

11. Treatment Resistant Depression Emerging Therapies

12. Treatment Resistant Depression Market Outlook

13. Country-Wise Treatment Resistant Depression Market Analysis (2019–2032)

14. Treatment Resistant Depression Market Access and Reimbursement of Therapies

15. Treatment Resistant Depression Market Drivers

16. Treatment Resistant Depression Market Barriers

17. Treatment Resistant Depression Appendix

18. Treatment Resistant Depression Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Treatment Resistant Depression Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutic

Airflow Heating & Air Conditioning Offers Expert Air Conditioning Repair Services in Skokie, IL

Airflow Heating & Air Conditioning offers expert AC repair services in Skokie, IL, ensuring fast, reliable solutions with certified technicians and same-day service.

Skokie, IL – January 29, 2025 – Airflow Heating & Air Conditioning, a trusted provider of HVAC solutions, is proud to offer top-tier air conditioning repair services to homeowners and businesses in Skokie, IL, and the surrounding areas. With years of expertise in the industry, the company ensures fast, efficient, and reliable solutions to keep indoor spaces comfortable year-round.

As temperatures fluctuate, a fully functional air conditioning system is essential for maintaining a comfortable and energy-efficient environment. Airflow Heating & Air Conditioning specializes in diagnosing and repairing AC units of all makes and models, addressing issues such as insufficient cooling, strange noises, refrigerant leaks, and system breakdowns. Their team of certified technicians is committed to delivering prompt and effective services to restore optimal performance to air conditioning units.

“Customer satisfaction and comfort are our top priorities”. “We understand the urgency of AC issues, especially during extreme weather conditions. Our expert team is dedicated to providing same-day and emergency repair services to ensure that our clients’ cooling systems function efficiently.”

Why Choose Airflow Heating & Air Conditioning for AC Repairs?

Certified and Experienced Technicians – Skilled professionals with extensive knowledge of AC systems.
Fast and Reliable Service – Same-day and emergency repair options available.
Comprehensive Diagnostics – Thorough inspections to identify and resolve issues effectively.
Affordable Pricing – Transparent pricing with no hidden fees.
Customer Satisfaction Guaranteed – High-quality repairs backed by a commitment to excellence.

In addition to air conditioning repair, Airflow Heating & Air Conditioning provides a full range of HVAC services, including AC installation, maintenance, heating solutions, and indoor air quality improvements.

Residents and businesses in Skokie, IL, looking for dependable air conditioning repair services can contact Airflow Heating & Air Conditioning at:

Call us today at (877) 538-1584 to schedule your service or visit us online to explore our full range of services.

About Airflow Heating & Air Conditioning

Airflow Heating & Air Conditioning is a leading HVAC company serving Skokie, IL, and surrounding communities. Specializing in air conditioning and heating services, the company is dedicated to providing high-quality solutions that enhance comfort and energy efficiency for residential and commercial customers. With a commitment to excellence, their team ensures top-notch service and customer satisfaction.

Media Contact
Company Name: AirFLow Heating and AC
Contact Person: Yoram Danino
Email: Send Email
Phone: (877) 538-1584
Address:9052 Terminal Ave.
City: Skokie
State: IL 60077
Country: United States
Website: https://airflowac.com/

Fibrodysplasia Ossificans Progressiva Market Set to Grow Substantially Through 2032, DelveInsight Projects | Ipsen, Regeneron Pharmaceutical, Biocryst

The Key Fibrodysplasia Ossificans Progressiva Companies in the market include – Ipsen, Regeneron Pharmaceutical, Biocryst,, and others.

The Fibrodysplasia Ossificans Progressiva market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fibrodysplasia Ossificans Progressiva pipeline products will significantly revolutionize the Fibrodysplasia Ossificans Progressiva market dynamics.

DelveInsight’s “Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fibrodysplasia Ossificans Progressiva, historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Fibrodysplasia Ossificans Progressiva market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Fibrodysplasia Ossificans Progressiva market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fibrodysplasia Ossificans Progressiva Market Forecast

Some of the key facts of the Fibrodysplasia Ossificans Progressiva Market Report:

The Fibrodysplasia Ossificans Progressiva market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In January 2025, āshibio, a privately held, clinical-stage biotechnology company developing innovative therapeutics for severe bone and connective tissue disorders, announced today that the first participant has been dosed in its ANDECAL study. This Phase 2/3 clinical trial is assessing the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of andecaliximab in patients with fibrodysplasia ossificans progressiva (FOP). The dosing of andecaliximab, āshibio’s lead product candidate, represents a significant milestone in the company’s first clinical trial targeting conditions associated with heterotopic ossification (HO), a pathological process that leads to abnormal bone formation in soft tissues like muscles, tendons, and ligaments.
According to NORD, Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles
Among the 7MM, the United States is likely to dominate the Fibrodysplasia Ossificans Progressiva treatment market due to the suitable healthcare infrastructure
According to a study by Moira et al., the prevalence of Fibrodysplasia Ossificans Progressiva is approximately 0.65 per million in North America, 0.47 per million in Western Europe, and 0.27 per million in Latin America to 0.05 per million in Africa and nearly 0.04 per million in the Asia-Pacific region.
Key Fibrodysplasia Ossificans Progressiva Companies: Ipsen, Regeneron Pharmaceutical, Biocryst,, and others
Key Fibrodysplasia Ossificans Progressiva Therapies: Palovarotene, Garetosmab, BCX9250, and others
The Fibrodysplasia Ossificans Progressiva epidemiology based on gender analyzed that females are more prevalent for Fibrodysplasia Ossificans Progressiva rather than males. It has been found that 54% females and 46% males are affected with Fibrodysplasia Ossificans Progressiva

Fibrodysplasia Ossificans Progressiva Overview

Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body’s skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible.

Get a Free sample for the Fibrodysplasia Ossificans Progressiva Market Report:

https://www.delveinsight.com/report-store/fibrodysplasia-ossificans-progressiva-fop-market

Fibrodysplasia Ossificans Progressiva Epidemiology

Fibrodysplasia Ossificans Progressiva Epidemiology Segmentation:

The Fibrodysplasia Ossificans Progressiva market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Fibrodysplasia Ossificans Progressiva
Prevalent Cases of Fibrodysplasia Ossificans Progressiva by severity
Gender-specific Prevalence of Fibrodysplasia Ossificans Progressiva
Diagnosed Cases of Episodic and Chronic Fibrodysplasia Ossificans Progressiva

Download the report to understand which factors are driving Fibrodysplasia Ossificans Progressiva epidemiology trends @ Fibrodysplasia Ossificans Progressiva Epidemiological Insights

Fibrodysplasia Ossificans Progressiva Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fibrodysplasia Ossificans Progressiva market or expected to get launched during the study period. The analysis covers Fibrodysplasia Ossificans Progressiva market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on

market share. The report also covers the Fibrodysplasia Ossificans Progressiva Pipeline

Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fibrodysplasia Ossificans Progressiva Therapies and Key Companies

Palovarotene: Ipsen
Garetosmab: Regeneron Pharmaceutical
Biocryst: BCX9250

To know more about Fibrodysplasia Ossificans Progressiva treatment, visit @ Fibrodysplasia Ossificans Progressiva Medications

Fibrodysplasia Ossificans Progressiva Market Drivers

Increased Awareness and Diagnosis
Rising Research and Development
Emerging Therapies
Strong Patient Advocacy
Supportive Regulatory Environment
Potential for Rare Disease Market Growth

Fibrodysplasia Ossificans Progressiva Market Barriers

Limited Treatment Options
High Cost of Treatments
Small Patient Population
Complexity in Drug Development
Long Development Timelines

Scope of the Fibrodysplasia Ossificans Progressiva Market Repor

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Fibrodysplasia Ossificans Progressiva Companies: Ipsen, Regeneron Pharmaceutical, Biocryst, and others
Key Fibrodysplasia Ossificans Progressiva Therapies: Palovarotene, Garetosmab, BCX9250, and others
Fibrodysplasia Ossificans Progressiva Therapeutic Assessment: Fibrodysplasia Ossificans Progressiva current marketed and Fibrodysplasia Ossificans Progressiva emerging therapies
Fibrodysplasia Ossificans Progressiva Market Dynamics: Fibrodysplasia Ossificans Progressiva market drivers and Fibrodysplasia Ossificans Progressiva market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Fibrodysplasia Ossificans Progressiva Unmet Needs, KOL’s views, Analyst’s views, FibrodysplasiaOssificans Progressiva Market Access and Reimbursement

Discover more about therapies set to grab major Fibrodysplasia Ossificans Progressiva market share @ Fibrodysplasia Ossificans Progressiva Treatment Landscape

Table of Contents

1. Fibrodysplasia Ossificans Progressiva Market Report Introduction

2. Executive Summary for Fibrodysplasia Ossificans Progressiva

3. SWOT analysis of Fibrodysplasia Ossificans Progressiva

4. Fibrodysplasia Ossificans Progressiva Patient Share (%) Overview at a Glance

5. Fibrodysplasia Ossificans Progressiva Market Overview at a Glance

6. Fibrodysplasia Ossificans Progressiva Disease Background and Overview

7. Fibrodysplasia Ossificans Progressiva Epidemiology and Patient Population

8. Country-Specific Patient Population of Fibrodysplasia Ossificans Progressiva

9. Fibrodysplasia Ossificans Progressiva Current Treatment and Medical Practices

10. Fibrodysplasia Ossificans Progressiva Unmet Needs

11. Fibrodysplasia Ossificans Progressiva Emerging Therapies

12. Fibrodysplasia Ossificans Progressiva Market Outlook

13. Country-Wise Fibrodysplasia Ossificans Progressiva Market Analysis (2019–2032)

14. Fibrodysplasia Ossificans Progressiva Market Access and Reimbursement of Therapies

15. Fibrodysplasia Ossificans Progressiva Market Drivers

16. Fibrodysplasia Ossificans Progressiva Market Barriers

17. Fibrodysplasia Ossificans Progressiva Appendix

18. Fibrodysplasia Ossificans Progressiva Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fibrodysplasia Ossificans Progressiva Market Set to Grow Substantially Through 2032, DelveInsight Projects | Ipsen, Regeneron Pharmaceutical, Biocryst